Stifel analyst Thomas Stephan upgraded Sight Sciences to Buy from Hold with a price target of $15, up from $10.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGHT:
- Sight Sciences, Verana Health collaborate on glaucoma research
- Sight Sciences price target raised to $15 from $10 at Citi
- Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months
- Sight Sciences announces independent data on TearCare treatment
- Needham healthcare analyst to hold an analyst/industry conference call